Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour

Lancet

Volumn 348, Issue 9030, 1996, Pages 771-775

  Boersma, Eric ^a   Maas, Arthur C P ^a   Deckers, Jaap W ^a   Simoons, Maarten L ^a,b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SYMPTOM;

EID: 0030596903     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)02514-7     Document Type: Article

References (52)

1. Vermeer F, Simoons ML, Bär FW, et al. Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase. Circulation 1986, 74: 1379-89.
2. Weaver WD. Time to thrombolytic treatment: factors affecting delay and their influence on outcome. J Am Coll Cardiol 1995; 25: 3S-9S.
3. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death: 1 myocardial infarct size versus duration of coronary occlusion in dogs. Circulation 1977; 56: 786-94.
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
5. Flameng W, Lesaffre E, Vanhaecke J Determinants of infarct size in non-human primates. Bas Res Cardiol. 85:1990;392-403.
6. Reimer KA, Vander Heide RS, Richard VJ Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models. Am J Cardiol. 72:1993;13G-21G.
7. Dorado DG, Théroux P, Elizaga J, et al. Myocardial infarction in the pig heart model: infarct size and duration of coronary occlusion. Cardiovasc Res 1987; 21: 537-44.
8. 2 on tissue-ATP content in ischemic and infarcted myocardium. J Mol Cell Cardiol. 19:1987;19-37.
9. Hermens WT, Willems GM, Nijssen KM, Simoons ML Effect of thrombolytic treatment delay on myocardial infarction size. Lancet. 340:1992;1297.
10. McNeill AJ, Flannery DJ, Wilson CM, et al. Thrombolytic therapy within one hour of the onset of acute myocardial infarction. Q J Med 1991; 79: 487-94.
11. Davies GJ, Chierchia S, Maseri A. Prevention of myocardial infarction by very early treatment with intracoronary streptokinase. N Engl J Med 1984; 311: 1488-92.
12. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico (GISSI) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. i:1986;397-401.
13. Van de Werf F, Arnold AER, for the European Cooperative Study Group for recombinant tissue type plasminogen activator: intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. BMJ 1988; 297: 1374-79.
14. McNeill AJ, Cunningham SR, Flannery DJ, et al. A double-blind placebo-controlled study of early and late adminstration of recombinant tissue plasminogen activator in acute myocardial infarction. Br Heart J 1989; 61: 316-21.
15. Schofer J, Büttner J, Geng G, et al. Prehospital thrombolysis in acute myocardial infarction. Am J Cardiol 1990; 66: 1429-33.
16. Barbash GI, Roth A, Hod H, et al. Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 261-66.
17. Castaigne AD, Hervé C, Duval-Moulin AMet al. Pre-hospital use of APSAC: results of a placebo-controlled study. Am J Cardiol. 64:1989;30A-33A.
18. McAleer B, Ruane B, Burke E, et al. Prehospital thrombolysis in a rural community: short and long-term survival. Cardiovasc Drugs Ther 1992; 6: 369-72.
19. Great Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. BMJ 1992; 305: 548-53.
20. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270: 1211-16.
21. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 383-89.
22. Fath-Ordoubadi F, Al-Mohammad A, Huehns TY, Beat KJ. Meta-analysis of randomised trials of prehospital versus hospital thrombolysis. Circulation 1994; 90: I-325 (abstr).
23. Fath-Ordoubadi F, Beatt KJ Fibrinolytic therapy in suspected acute myocardial infarction. Lancet. 343:1994;912.
24. Honan MB, Harrell FE, Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol 1990; 16: 359-67.
25. Kennedy JW, Ritchie JL, Davies KB, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477-82.
26. Verstraete M, Bleifeld W, Brower RW, et al. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985; ii: 965-99.
27. Simoons ML, Serruys PW, Van den Brand M, et al. Improved survival after early thrombolysis in acute myocardial infarction: a randomised trial by the Interuniversity Cardiology Institute in The Netherlands. Lancet 1985; ii: 578-82.
28. Ikram S, Lewis S, Bucknall C, et al. Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. BMJ 1986; 293: 786-89.
29. The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314: 1465-71.
30. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317: 850-55.
31. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-60.
32. AIMS (APSAC Intervention Mortality Study) Trial Study Group. Effects of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; i: 545-49.
33. Wilcox RG, Von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; ii: 525-30.
34. Brunelli C, Spallarossa P, Ghigliotti G, et al. Peaking time of creatine-kinase MB in patients treated with urokinase or conventionally during acute myocardial infarction: is it really a clue to reperfusion? Cardiologia 1988; 33: 669-74.
35. National Heart Foundation of Australia coronary thrombolysis group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 h after onset of myocardial infarction. Lancet 1988; i: 203-07.
36. O'Rourke M, Baron D, Keogh A, et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988; 77: 1311-15.
37. Kennedy JW, Martin GV, David KB, et al. The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation 1988; 77: 345-52.
38. Rentrop KP, Feit F, Sherman W, Thornton JC. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction: report from the second Mount Sinai-New York University reperfusion trial. Circulation 1989; 90: 1166-75.
39. Armstrong PW, Baigrie RS, Daly PA, et al. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol 1989; 13: 1469-76.
40. The Thrombolysis Early in Acute Heart Attack Trial study group. Very early thrombolytic therapy in suspected acute myocardial infarction. Am J Cardiol 1990; 65: 401-07.
41. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 h after onset of acute myocardial infarction. Lancet 1993; 342: 759-66.
42. EMERAS (Estudio Multicentrico Esteptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767-72.
43. Rossi P, Bolognese L, on behalf of Urochinasi per la Sistemica nell'Infarto Myocardico (USIM) Collaborative Group. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Am J Cardiol 1991; 68: 585-92.
44. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
45. Brunelli C, Spallarossa P, Ghigliotta G, Ianetti M, Caponnetto S. Thrombolysis in refractory unstable angina. Am J Cardiol 1991; 68: 110B-18B.
46. Bär FW, Verheugt FW, Col J, et al. Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome: results of UNASEM, a multicenter, randomised, placebo-controlled, clincial trial with anistreplase. Circulation 1992; 86: 131-37.
47. The TIMI IIIB investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation 1994; 89: 1545-56.
48. Simoons ML, Arnold AER. Tailored thrombolytic therapy. A perspective. Circulation 1993; 88: 2556-64.
49. Turi ZG, Stone PH, Muller JE. Implications for acute intervention related to time of hospital arrival in acute myocardial infarction. Am J Cardiol 1986; 58: 203-09.
50. Yarzebski J, Goldberg RJ, Gore JM, Alpert JS. Temporal trends and factors associated with extent of delay to hospital arrival in patients with acute myocardial infarction: the Worcester heart attack study. Am Heart J 1994; 128: 255-63.
51. Bouten MJM, Simoons ML, Hartman JAM, Van Miltenburg AJM, Van der Does E, Pool J. Prehospital thrombolysis with alteplase (rt-PA) in acute myocardial infarction. Eur J Heart 1992; 13: 925-31.
52. Guidelines. Acute myocardial infarction: pre-hospital and in-hospital management. The task force on the management of acute myocardial infarction of the European society of cardiology. Eur Heart J 1996; 17: 43-63.